Investors in Academic Research

SIFEM is the Swiss Development Finance Institution (DFI). It is owned by the Swiss Government and an integral part of Switzerland's International Cooperation Strategy. SIFEM provides long-term financing through financial intermediaries to SMEs and other fast-growing companies in developing countries. It aims to reduce poverty and foster sustainable, inclusive and resilient economies by creating and securing more and better jobs, growing opportunities for the underserved and supporting projects towards a Just Transition. SIFEM aligns its investments with international environmental goals to address the global climate crisis and support emerging markets in achieving low-carbon economic growth. With its investments it contributes to closing financing gaps and mobilising additional private capital for the growth of local companies in developing countries. By the end of 2022, SIFEM's investment portfolio amounts to USD 451m, thereby financing directly and indirectly 612 companies in 80 countries. Since its inception, SIFEM made commitments of almost USD 1.3 billion.

Sustainable Ventures is a catalyst for climate startups and entrepreneurs, offering comprehensive support to scale from inception to exit. They specialize in providing investment, workspaces, and venture support tailored to the unique needs of sustainable businesses. Sustainable Ventures is committed to fostering innovation in climate solutions, aiming to accelerate the growth and impact of startups dedicated to environmental sustainability. With a strategic approach and deep sector expertise, they play a pivotal role in nurturing and advancing the next generation of climate-focused enterprises.

Genextra is a privately owned holding company with investments in early-stage life science companies. Our mission is to identify innovative research in life science and to advance novel therapies and tools by creating successful business initiatives.

Monograph Capital is a venture firm focused on life sciences. With a dedicated emphasis on the life sciences sector, Monograph Capital invests in innovative companies and technologies that aim to advance healthcare and biotechnology. The firm supports early-stage ventures as well as growth-stage companies, providing critical capital, strategic guidance, and industry expertise to drive their development and success. Monograph Capital's investments span across biotech, pharmaceuticals, medical devices, and other areas within the life sciences field, aiming to contribute to breakthrough discoveries, therapies, and medical advancements. Through its strategic investments, Monograph Capital plays a crucial role in accelerating innovation and improving health outcomes globally.

MVM Life Science Partners, we are a specialized healthcare investment firm focused on early-stage and growth-stage companies in the life sciences sector. Founded in 1997 and headquartered in London, our firm invests globally in innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. Our approach combines deep sector expertise with strategic support to help our portfolio companies achieve their full potential. We have a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide.

HS LifeSciences was established in 2008 by seasoned biotech entrepreneurs with many years of experience in managing biotech companies. The lessons learned over the years have been distilled into a new business model centered on the foundation and growth of new life sciences companies without the need for conventional multiple rounds of equity-based financing.

Valide.no supports researchers and entrepreneurs in commercializing innovative solutions with expertise, networking, and capital, contributing to a better world through research-based products and ideas

Birk Venture is a company based in Oslo, Norway, dedicated to transforming unique innovations and technologies into successful businesses in the healthcare sector. They focus on leveraging cutting-edge technologies in life science to meet the increasin.